TABLE E3.
Metabolites significantly different by phenotype
| Food-allergic (n = 12) vs control (n = 37, reference) |
Food-sensitive (n = 32) vs control (n = 37, reference) |
Food-allergic (n = 12) vs food-sensitive (n = 32, reference) |
||||||
|---|---|---|---|---|---|---|---|---|
| Metabolite | Odds ratio (95% CI) | P value | Metabolite | Odds ratio (95% CI) | P value | Metabolite | Odds ratio (95% CI) | P value |
| 7-Methylguanine | 0.29 (0.11–0.63) | .004 | 3-Ketosphinganine | 2.49 (1.37–4.89) | .004 | 3-Hydroxypalmitate | 0.23 (0.07–0.59) | .01 |
| Docosapentaenoate (n3 DPA; 22:5n3) | 0.24 (0.07–0.64) | .01 | Pimelate (heptanedioate) | 2.83 (1.38–6.29) | .01 | Ribonate | 0.32 (0.13–0.69) | .01 |
| 2-Aminophenol | 3.20 (1.40–8.68) | .01 | Pyridoxine (vitamin B6) | 3.08 (1.40–7.63) | .01 | 1-Palmitoyl-GPI (16:0) | 0.25 (0.08–0.63) | .01 |
| Bilirubin (E,Z or Z,E)* | 0.20 (0.05–0.62) | .01 | Cis-urocanate | 0.24 (0.07–0.66) | .01 | 1-Palmitoyl-GPS (16:0)* | 0.25 (0.08–0.65) | .01 |
| Histidine | 0.11 (0.01–0.53) | .01 | Diacetylchitobiose | 0.38 (0.16, -0.79) | .01 | I-urobilinogen | 0.42 (0.20–0.79) | .01 |
| N-formylmethionine | 0.28 (0.09–0.72) | .01 | N-acetylglutamate | 0.25 (0.07–0.73) | .02 | Sphinganine | 0.15 (0.03–0.56) | .01 |
| I-urobilinogen | 0.43 (0.20–0.82) | .02 | 5alpha-pregnan-3beta,20alpha-diol monosulfate (1) | 3.04 (1.31–8.77) | .02 | 2-Methylserine | 0.32 (0.11–0.75) | .02 |
| Dihomo-linolenate (20:3n3 or n6) | 0.25 (0.06–0.66) | .02 | N-carbamoylaspartate | 0.38 (0.15–0.81) | .02 | 13-Methylmyristate | 0.39 (0.17–0.82) | .02 |
| Serine | 0.11 (0.01–0.59) | .02 | N-acetylasparagine | 0.26 (0.08–0.78) | .02 | Dihomo-linolenate (20:3n3 or n6) | 0.24 (0.06–0.67) | .02 |
| 2-Methylserine | 0.20 (0.04–0.68) | .03 | Lysylleucine | 2.23 (1.15–4.69) | .02 | Glycylisoleucine | 0.25 (0.07–0.70) | .02 |
| 5,6-Dihydrothymine | 0.40 (0.16–0.86) | .03 | Vanillic alcohol sulfate | 0.42 (0.18–0.86) | .03 | D-urobilin | 0.40 (0.17–0.83) | .02 |
| 3-Hydroxypalmitate | 0.27 (0.07–0.79) | .03 | Docosahexenoylcarnitine (C22:6)* | 0.37 (0.14–0.83) | .03 | Docosapentaenoate (n3 DPA; 22:5n3) | 0.26 (0.07–0.74) | .02 |
| Phenethylamine | 0.32 (0.10–0.83) | .03 | Ursodeoxycholate sulfate (1) | 0.57 (0.34–0.92) | .03 | 7-Methylguanine | 0.47 (0.23–0.90) | .03 |
| D-urobilin | 0.42 (0.18–0.91) | .04 | 3-Methylglutarate/2-methylglutarate | 2.35 (1.14–5.35) | .03 | Sucrose | 0.37 (0.14–0.85) | .03 |
| Ursodeoxycholate sulfate (1) | 0.45 (0.20–0.90) | .04 | N-palmitoylserine | 1.87 (1.08–3.36) | .03 | 1-Palmitoyl-GPE (16:0) | 0.20 (0.04–0.73) | .03 |
| Tryptamine | 0.44 (0.19–0.90) | .04 | Malonylcarnitine | 0.39 (0.16–0.87) | .03 | 21-Hydroxypregnenolone disulfate | 0.31 (0.09–0.80) | .03 |
| 2,3-Dimethylsuccinate | 3.06 (1.09–9.72) | .04 | 13-Methylmyristate | 1.97 (1.08–3.80) | .03 | N-acetylglycine | 3.33 (1.21–11.18) | .03 |
| Oleoyl-linoleoyl-glycerol (18:1/18:2) [1] | 2.56 (1.09–6.94) | .04 | Dopamine 3-O-sulfate | 0.45 (0.21–0.90) | .03 | Alpha-CEHC | 0.32 (0.10–0.840) | .03 |
| Palmitoyl-linoleoyl-glycerol (16:0/18:2) [1]* | 2.56 (1.08–7.07) | .04 | Glutaminylleucine | 2.58 (1.12–6.57) | .03 | Glycerophosphoserine* | 0.28 (0.08–0.82) | .03 |
| Tyrosine | 0.16 (0.02–0.86) | .04 | N2,N6-diacetyllysine | 0.41 (0.17–0.90) | .03 | Bilirubin (E,Z or Z,E)* | 0.32 (0.10–0.87) | .04 |
| Formiminoglutamate | 0.36 (0.11–0.90) | .04 | N-acetyl-aspartyl-glutamate (NAAG) | 0.41 (0.17–0.91) | .04 | Glycylvaline | 0.24 (0.05–0.87) | .04 |
| Linolenate (alpha or gamma; [18:3n3 or 6]) | 0.27 (0.06–0.86) | .04 | N-alpha-acetylornithine | 0.39 (0.15–0.91) | .04 | Linoleoyl ethanolamide | 0.42 (0.17–0.94) | .04 |
| Linoleoyl-linolenoyl-glycerol (18:2/18:3) [2]* | 2.39 (1.04–6.06) | .05 | Allo-threonine | 0.40 (0.15–0.90) | .04 | |||
| 3-Ureidoisobutyrate | 0.45 (0.19–0.95) | .05 | Homoarginine | 1.79 (1.05–3.20) | .04 | |||
| Lactobionate | 0.43 (0.18–0.93) | .04 | ||||||
| 2,3-Dimethylsuccinate | 2.28 (1.07–5.46) | .04 | ||||||
| Chiro-inositol | 2.07 (1.05–4.38) | .04 | ||||||
Only metabolites with significant (P < .05) associations in age-adjusted analyses are shown.
*
Compounds with annotations that have not been officially confirmed on the basis of a standard.